A peptide dosage chart, one peptide at a time: its dose range, how often it’s taken, a typical run and the units on your syringe. All 69 peptides in the PepVault library.
A community reference, not medical advice. Each range is what has been studied or is commonly run, never a dose for you.
The 69 peptides in the PepVault library, each with its dose range (the range an FDA label gives, or the range studied in research), how often it's taken, a typical run, its half-life and how strong the evidence is. Open one for its full answer and the range as units on your own insulin syringe.
| Peptide | Dose range | How often | A typical run | Half-life | Evidence | Goal |
|---|---|---|---|---|---|---|
| BPC-157 | 200–500 mcg | 1–2× daily | 4–12 weeks | ~4–6 hours | Emerging | Healing |
| TB-500 | 1–2.5 mg | 2× weekly | 4–8 weeks | ~0.5–2 hours | Emerging | Healing |
| GHK-Cu | 1–2 mg | Daily | 8–12 weeks | Not measured | Emerging | Healing |
| KPV | 100–300 mcg | Daily | 4–8 weeks | Not measured | Emerging | Healing |
| AOD-9604 | 250–300 mcg | Daily | — | ~30 min | Moderate | Healing |
| Thymosin Alpha-1 | 1–1.6 mg | 2× weekly | — | ~2 hours | Established | Healing |
| Thymosin Beta-4 | 2–2.5 mg | Weekly | — | ~0.5–2 hours | Emerging | Healing |
| LL-37 | 100–300 mcg | Daily | — | Not measured | Emerging | Healing |
| Larazotide | 0.5–1 mg | 3× daily | — | Not measured | Moderate | Healing |
| VIP | 50 mcg | 2× daily | — | ~2 min IV | Moderate | Healing |
| ARA-290 | 1–4 mg | Daily | 4 weeks, often repeated | ~20 minutes | Moderate | Healing |
| Cartalax | No reference dose | Daily | Courses of 10–30 days (community practice) | Not measured | Emerging | Healing |
| Ac-SDKP | 250–750 mcg | EOD | — | ~4.5 min | Emerging | Healing |
| Ipamorelin | 200–300 mcg | 2–3× daily | 8–16 weeks | ~2 hours | Moderate | Growth hormone |
| CJC-1295 with DAC | 1–2 mg | Weekly | 8–12 weeks | ~6–8 days | Moderate | Growth hormone |
| CJC-1295 no DAC | 100–200 mcg | 2–3× daily | 8–12 weeks | ~30 min | Moderate | Growth hormone |
| Sermorelin | 200–500 mcg | Daily | 3–6 months | ~11–12 min | Established | Growth hormone |
| Tesamorelin | 1–2 mg | Daily | — | ~8–11 min | Established | Growth hormone |
| GHRP-2 | 100–300 mcg | 2–3× daily | — | ~30 min | Moderate | Growth hormone |
| GHRP-6 | 100–300 mcg | 2–3× daily | — | ~20 min | Moderate | Growth hormone |
| Hexarelin | 100–200 mcg | 2–3× daily | — | ~55–70 min | Moderate | Growth hormone |
| MK-677 | 10–25 mg | Daily | 8–16 weeks | ~24 hours | Moderate | Growth hormone |
| Fragment 176-191 | 250–500 mcg | Daily | — | ~30 min | Moderate | Growth hormone |
| IGF-1 LR3 | 20–50 mcg | Daily | 3–6 weeks per community cycle | Not measured | Emerging | Growth hormone |
| PEG-MGF | 200–400 mcg | 2–3× weekly | 8–16 weeks per community cycle | Not measured | Emerging | Growth hormone |
| Follistatin-344 | 100–200 mcg | Daily | 10–30 days per community cycle | Not measured | Emerging | Growth hormone |
| HGH | 1–4 IU | Daily | — | ~3-4 hours | Established | Growth hormone |
| Semaglutide | 0.25–2.4 mg | Weekly | Ongoing | ~1 week | Established | GLP-1 & metabolic |
| Semaglutide (oral) | 1.5–25 mg | Daily | — | ~1 week | Established | GLP-1 & metabolic |
| Tirzepatide | 2.5–15 mg | Weekly | Ongoing | ~5 days | Established | GLP-1 & metabolic |
| Retatrutide | 1–12 mg | Weekly | Ongoing | ~6 days | Established | GLP-1 & metabolic |
| Liraglutide | 0.6–3 mg | Daily | — | ~13 hours | Established | GLP-1 & metabolic |
| Dulaglutide | 0.75–4.5 mg | Weekly | Ongoing | ~5 days | Established | GLP-1 & metabolic |
| Orforglipron | 0.8–17.2 mg | Daily | Ongoing | ~29–49 hours | Established | GLP-1 & metabolic |
| Survodutide | 0.3–6 mg | Weekly | Ongoing | Not measured | Established | GLP-1 & metabolic |
| Mazdutide | 2–6 mg | Weekly | Ongoing | ~10 days | Established | GLP-1 & metabolic |
| Pemvidutide | 1.2–2.4 mg | Weekly | Ongoing | Not measured | Moderate | GLP-1 & metabolic |
| Cagrilintide | 0.25–2.4 mg | Weekly | Ongoing | ~1 week | Established | GLP-1 & metabolic |
| CagriSema | 0.25–2.4 mg | Weekly | Ongoing | Not measured | Established | GLP-1 & metabolic |
| 5-Amino-1MQ | 50–100 mg | Daily | — | Not measured | Emerging | GLP-1 & metabolic |
| SLU-PP-332 | 250–1000 mcg | Daily | About 8 weeks (community runs) | Not measured | Emerging | GLP-1 & metabolic |
| Oxytocin | 10–40 IU | 1–2× daily | — | ~1–6 min | Moderate | GLP-1 & metabolic |
| MOTS-c | 5–10 mg | 2–3× weekly | 4–8 weeks | Not measured | Emerging | Longevity |
| NAD+ | 50–100 mg | Daily | 2–6 week blocks | Not measured | Emerging | Longevity |
| Glutathione | 100–600 mg | Daily | Ongoing or in blocks | ~14 min | Emerging | Longevity |
| Epitalon | 5–10 mg | Daily | — | Not measured | Moderate | Longevity |
| Humanin | 2–4 mg | Weekly | — | Not measured | Emerging | Longevity |
| FOXO4-DRI | 1–2 mg | 3× weekly | — | Not measured | Emerging | Longevity |
| SS-31 | 2–4 mg | Daily | — | Not measured | Emerging | Longevity |
| Pinealon | 100–200 mcg | Daily | — | Not measured | Emerging | Longevity |
| Vesugen | No reference dose | Daily | Courses of 10–30 days (community practice) | Not measured | Emerging | Longevity |
| Klotho | 0.01–0.1 mg | Weekly | — | Not measured | Emerging | Longevity |
| NMN | 250–1000 mg | Daily | — | Not measured | Moderate | Longevity |
| SNAP-8 | 3–10% | 1–2× daily | Ongoing (studies ran 4–12 weeks) | Not measured | Emerging | Longevity |
| DSIP | 200–400 mcg | Daily | — | Not measured | Emerging | Longevity |
| Dihexa | 10–30 mg | Daily | — | Not measured | Emerging | Cognitive |
| Selank | 250–500 mcg | Daily | 10–21 days | ~10 min in blood | Moderate | Cognitive |
| Semax | 200–900 mcg | Daily | 10–30 days | Not measured | Moderate | Cognitive |
| NSI-189 | 40–80 mg | Daily | — | Not measured | Emerging | Cognitive |
| P21 | 100–300 mcg | Daily | — | Not measured | Emerging | Cognitive |
| Cerebrolysin | 5–10 mL | Daily | — | Not measured | Established | Cognitive |
| N-Acetyl Semax Amidate | 100–600 mcg | Daily | — | Not measured | Emerging | Cognitive |
| Adamax | No reference dose | Daily | Not established (no study) | Not measured | Emerging | Cognitive |
| PT-141 | 0.5–2 mg | As needed | As needed | ~2.7 hours | Established | Sexual health |
| Gonadorelin | 100 mcg | 2–3× weekly | — | ~2–10 min | Established | Sexual health |
| Kisspeptin-10 | 50–500 mcg | 2–3× weekly | — | ~4 min | Emerging | Sexual health |
| Enclomiphene | 12.5–25 mg | Daily | — | ~10 hours | Moderate | Sexual health |
| Melanotan II | 250–500 mcg | Daily | Loading 1–2 weeks, then maintenance ongoing | Not measured | Emerging | Sexual health |
| Melanotan I | 250–1000 mcg | Daily | Loading 10–14 days, then maintenance | ~0.8–1.7 hours | Established | Sexual health |
PepVault logs every dose, keeps count of the doses left in your vials, and reminds you on your schedule.
Get PepVault on the App Store7 days free on the yearly plan for new subscribers.
A community reference, not medical advice. Each range is what has been studied or is commonly run, never a dose for you.
Newsletter · Weekly
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.